Loading
A phase 1/2 trial of Ibrutinib in brain and spinal cord tumours, run by Curis, Inc., now recruiting.
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) is a phase 1/2 interventional study registered as NCT03328078 by Curis, Inc., with 152 participants planned, started 2017-12-28 and due to reach its primary completion in 2026-08. Interventions recorded: Emavusertib and Ibrutinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Emavusertib, Curis and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Ibrutinib and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/